Atara Biotherapeutics, Inc. (0HIY.L)

Atara Biotherapeutics, Inc. (0HIY.L) — VMCI valuation read

0HIY.L screens at VMCI 54/100, a 4-point gap above the Healthcare sector median (50). For a mid-cap Atara Biotherapeutics, Inc. share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.

0HIY.L has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: 0HIY.L trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of -2.2x leaves covenant headroom, which sets the rate-cycle exposure for Atara Biotherapeutics, Inc..

0HIY.L fell 1.6% over the trailing 7 days, with a -7.5% read on a 30-day basis.